VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients

Boston, MA 10/07/2014 (wallstreetpr) – VIVUS, Inc. (NASDAQ:VVUS) is claiming that its Qsymia has the potential to treat obese or overweight patients with type 2 diabetes. The company made the disclosure through its paper that was published online in the Diabetes Care journal. Studies Undertaken The paper elaborated the clinical results in which, Qsymia was found […]

VIVUS, Inc. (NASDAQ:VVUS) – Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use

Boston, MA 09/19/2014 (wallstreetpr) – Stendra, the erectile dysfunction drug developed collaboratively by VIVUS, Inc. (NASDAQ:VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) has been given the nod by the U.S. Food and Drug Administration to be used 15 minutes earlier. It is crucial to point out here that this drug was already approved by the FDA, […]

Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s Long-Awaited Obesity Pill Contrave Received FDA Nod

Boston, MA 09/12/2014 (wallstreetpr) – The U.S. Food and Drug Administration gave a green signal to Orexigen Therapeutics, Inc. (NASDAQ:OREX) diet pill called Contrave for sale in the country. The reason why this approval holds prominence is because it is the only third kind of obesity treatment/pill in over 10 years, which has received FDA’s […]

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Stock Plummets As FDA Delays Decision on Diet Drug

Boston, MA 06/12/2014 (wallstreetpr) – A bio-pharmaceutical company with a clear focus on obesity drug, Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced that the drug regulator has extended time by three months for the review of the resubmitted NDA or New Drug Application for its drug Contrave. It has been directly reflected in the stock market where […]

Why Orexigen Therapeutics, Inc. (NASDAQ:OREX) May Ride Smooth In Tricky Weight-Drug Market

Boston, MA 06/11/2014 (wallstreetpr) – Orexigen Therapeutics, Inc. (NASDAQ:OREX) intends to bring its obesity drug called Contrave to the market after the U.S. Food and Drug Administration issues its verdict today. The approval of the drug will be a milestone for the company given its many past challenges to bring the drug to the market. […]

Before the Market News: VIVUS, Inc. (NASDAQ:VVUS), Prospect Capital Corporation (NASDAQ:PSEC), EMC Corporation (NYSE:EMC)

Boston, MA 02/26/2014 (wallstreetpr) – VIVUS, Inc. (NASDAQ:VVUS) was source of bad news on Nasdaq as the company preferred silence to addressing the concerns around its obesity drug Qsymia. The stock fell more than 15 percent in early trading Tuesday and ended up touching a new 52-week low by bell time. The drug was once […]

Vivus Inc. (NASDAQ:VVUS) To Increase Board Strength

Boston, MA 05/14/2013 (wallstreetpr) – Amid intense criticism from shareholders on the poor strategy for marketing its obesity drug, Vivus Inc. (NASDAQ:VVUS) (closed: $13.50, Up by 4.17%) had now added two members to the board of directors. J.Martin Carroll and Jorge Plutzky had joined the board of the Mountain View, California based drugmaker, Vivus Inc. […]